TISSIUM CEO’s Vision Is To Make The Tissue Recon Label Stick
CEO Bancel Envisages TISSIUM As A Tissue Reconstruction Specialist Rather Than Simply A Provider Of A Technology
Christophe Bancel, CEO of French medtech innovator TISSIUM, has made a career in various parts of the health care products industry, identifying business opportunities, founding, directing and leading ventures, and planning for contingencies. The ex-Serono and UCB executive, who has had many other postings, is now testing his adaptability and leadership qualities by bringing a versatile class III synthetic polymer device into key markets.
You may also be interested in...
In its just-released real-world evidence framework, NICE assesses the role and value of data collected outside highly-controlled clinical studies in driving more innovation towards health care professionals.
Ukraine’s medical supply needs have evolved since Russia launched its military invasion of the country on 24 February. EU healthcare decision makers and the medical technology industry have since stood firm in their support of the besieged country, said MedTech Europe’s Jesús Rueda.
The role and purpose of medical device regulation is now better understood than at any time in its history, and regulators are no longer seen as gatekeepers preventing business from happening. In Vivo Rising Leader 2022 Graeme Tunbridge, formerly at the MHRA and now a senior VP at BSI, is a champion of the climate of inclusivity.